中国医学科学院北京协和医学院病原生物学研究所研究员，博士生导师。主要从事呼吸道病毒与宿主相互作用机制及其感染致病机制的研究。主持国家传染病重大专项和国家自然科学基金面上项目等多项国家级科研项目。在Nat Commun、Signal Transduct Target Ther、Cell Rep、PLoS Pathog、J Biol Chem、J Virol、Natl Sci Rev和FASEB J等SCI收录杂志上发表SCI论文24篇。入选2020年Springer Nature中国学者年度高影响力研究，2022年斯坦福大学全球前2%顶尖科学家榜单。目前担任中国微生物学会病毒学专业委员会委员和中华预防医学会医学病毒学分会青年小组委员。

重要呼吸道病毒与宿主相互作用研究

1.  国家自然科学基金面上项目，GSDME介导的细胞焦亡在肠道病毒71型感染致病机制中的作用研究，81971948，课题负责人；
2.  国家传染病重大专项，基于人类全基因组编码及非编码区高通量筛选的抗病毒靶标发现新技术研究，ZX201810301401，课题负责人；
3.  国家自然科学基金面上项目，高尔基体ACBD3蛋白复合物参与EV71复制的分子机制研究，81672032，课题负责人；
4.  中国医学科学院医学与健康科技创新工程，抗感染药物/疫苗快速评测与开发，2016-I2M-1-005，子课题负责人；
5.  国家重点研发计划，新型冠状病毒感染复制关键宿主因子及其作用机制研究，2020YFA0707600，课题骨干；
6.  国家自然科学基金重点项目，重要肠道病毒感染复制关键宿主因子全景式筛选及其作用分子机制研究，81930063，2020.01-2024.12，课题骨干。

代表性论文：(# 共同第一作者；* 共同通讯作者)
1.    Zhang D#, Qiao L#, Lei X#, Dong X, Tong Y, Wang J*, Wang Z*, Zhou R*. Mutagenesis and structural studies reveal the basis for the specific binding of SARS- CoV-2 SL3 RNA element with human TIA1 protein. Nat Commun. 2023 Jun 22; 14(1):3715.
2.    Wu Z#, Lei X#, Wang X#, Zhang Z, Li Y, Gao L, Liang X, Wang P, Wang J*, Ma C*. Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection. Signal Transduct Target Ther. 2023 Jan 18;8(1):19.
3.     Guo S#, Lei X#, Chang Y#, Zhao J#, Wang J#, Dong X, Liu Q, Zhang Z, Wang L, Yi D, Ma L, Li Q, Zhang Y, Ding J, Liang C, Li X, Guo F*, Wang J*, Cen S*. SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis. Signal Transduct Target Ther. 2022 Dec 27;7(1):400.
4.    Dong S#, Shi Y#, Dong X, Xiao X, Qi J, Ren L, Xiang Z, Zhou Z, Wang J*, Lei X*. Gasdermin E is required for induction of pyroptosis and severe disease during enterovirus 71 infection. J Biol Chem. 2022 May; 298(5): 101850.
5.    Zhou Z#, Zhang X#, Lei X#, Xiao X#, Jiao T, Ma R, Dong X, Jiang Q, Wang W, Shi Y, Zheng T, Rao J, Xiang Z, Ren L, Deng T, Jiang Z, Dou Z, Wei W*, Wang J*. Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection. Signal Transduct Target Ther. 2021 Nov 3; 6(1):382.
6.    Wang W#, Zhou Z#, Xiao X#, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X*, Xiang Z*, Wang J*. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol. 2021,18(4):945-953.
7.    Lei X#, Dong X#, Ma R#, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F, Zhao Z, Zhou Z*, Xiang Z*, Wang J*. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun, 2020, 11(1): 3810.
8.    Lei X#, Zhang Z#, Xiao X, Qi J, He B*, Wang J*. Enterovirus 71 Inhibits Pyroptosis through Cleavage of Gasdermin D. J Virol. 2017, 91(18): e01069-17.
9.    Xiao X#, Lei X#, Zhang Z, Ma Y, Qi J,Wu C, Xiao Y, Li L, He B*, Wang J*. Enterovirus 3A facilitates viral replication by promoting Phosphatidylinositol4-kinaseIIIβ-ACBD3 interaction. J Virol. 2017, 91(19): e00791-17.
10.    Wang H#, Lei X#, Xiao X, Yang C, Lu W, Huang Z, Leng Q, Jin Q, He B, Meng G*, Wang J*. Reciprocal Regulation between Enterovirus 71 and the NLRP3 Inflammasome. Cell Rep. 2015, 12(1): 42-48.
11.    Lei X#, Cui Sheng, Zhao Z*, Wang J*. Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease. Natl Sci Rev. 2015, 2 (3): 268-284.
12.    Lei X#, Han N#, Xiao X, Jin Q*, He B*, Wang J*. Enterovirus 71 3C inhibits cytokine expression through cleavage of the TAK1/TAB1/TAB2/TAB3 complex.  J Virol. 2014, 88(17): 9830-9841.
13.    Lei X, Xiao X，Xue Q，Jin Q*, He B*, Wang J*. Cleavage of Interferon Regulatory Factor 7 by Enterovirus 71 3C Suppresses Cellular Responses. J Virol. 2013，87（3）：1690-1698.
14.    Lei X#, Sun Z#, Liu X, Jin Q*, He B*, Wang J*.Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3，J Virol. 2011，85（17）：8811-8818.
15.    Lei X, Liu X, Ma Y, Sun Z, Yang Y, Jin Q*, He B*, Wang J*. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol. 2010, 84(16): 8051-8061.

团队累计培养研究生、博士后10人次